Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pharmacokinetics of oral edaravone in ALS
jRCT2080224962Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Pharmacokinetics of oral edaravone, Urinary excretion profile and 1 more. Started Nov 2019; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2080224962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224962.